Application of SELDI-TOF mass spectrometry for the identification of differentially expressed proteins in transformed follicular lymphoma

Modern Pathology

Volumn 17, Issue 6, 2004, Pages 670-678

  Lin, Zhaosheng ^a   Jenson, Stephen D ^b   Lim, Megan S ^a,b   Elenitoba Johnson, Kojo SJ ^a,b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Follicular lymphoma; Mass spectrometry; Proteomics; SELDI; Transformation

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; CYCLIN D3;

ARTICLE; CASE REPORT; CHROMATOGRAPHY; COMPUTER PROGRAM; FOLLICULAR LYMPHOMA; GENOME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MEDICAL GENETICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DATABASE; PROTEIN EXPRESSION; PROTEOMICS; SEPARATION TECHNIQUE; TIME OF FLIGHT MASS SPECTROMETRY; TUMOR GROWTH;

ANTIGENS, CD20; ANTIGENS, CD3; BLOTTING, WESTERN; CASPASE 3; CASPASES; CYCLINS; DNA-BINDING PROTEINS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, FOLLICULAR; POLYMERASE CHAIN REACTION; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-BCL-6; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSCRIPTION FACTORS;

EID: 2642540143     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800100     Document Type: Article

References (28)

1. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA 2001;286:2211-2214.
2. Fung ET, Wright Jr GL, Dalmasso EA. Proteomic strategies for biomarker identification: progress and challenges. Curr Opin Mol Ther 2000;2:643-650.
3. Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000;21:1164-1177.
4. Chapman K. The ProteinChip Biomarker System from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation. Biochem Soc Trans 2002;30:82-87.
5. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, VA, November 1997. J Clin Oncol 1999;17:3835-3849.
6. Link AJ, Eng J, Schieltz DM. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999;17:676-682.
7. Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999;17:994-999.
8. Paweletz CP, Trock B, Pennanen M, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001;17:301-307.
9. Issaq HJ, Veenstra TD, Conrads TP, et al. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292:587-592.
10. Fetsch PA, Simone NL, Bryant-Greenwood PK, et al. Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol 2002;118:870-876.
11. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491-1502.
12. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2000;359:572-577.
13. Sherr CJ. Cell cycle control and cancer. Harvey Lect 2000;96:73-92.
14. Bartkova J, Lukas J, Strauss M, et al. Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene 1998;17:1027-1037.
15. Williams ME, Westermann CD, Swerdlow SH. Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus. Blood 1990;76:1387-1391.
16. Rimokh R, Berger F, Bastard C, et al. Rearrangement of CCND1 (BCL1/PRAD1) 3′ untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood 1994;83:3689-3696.
17. Filipits M, Jaeger U, Pohl G, et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 2002;8:729-733.
18. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999;11:68-75.
19. Lee JM, Bernstein A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev 1995;14:149-161.
20. Kaufmann SH, Gores GJ. Apoptosis in cancer: cause and cure. Bioessays 2000;22:1007-1017.
21. Dixit VM. Role of ICE-proteases in apoptosis. Adv Exp Med Biol 1996;406:113-117.
22. Krajewski S, Gascoyne RD, Zapata JM, et al. Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin's lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes. Blood 1997;89:3817-3825.
23. Armstrong RC, Aia T, Xiang J, et al. Fas-induced activation of the cell death-related protease CPP32 Is inhibited by Bcl-2 and by ICE family protease inhibitors. J Biol Chem 1996;271:16850-16855.
24. Boulakia CA, Chen G, Ng FW, et al. Bcl-2 and adenovirus EIB 19kDa protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase. Oncogene 1996;12:529-535.
25. Chinnaiyan AM, Orth K, O'Rourke K, et al. Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases. J Biol Chem 1996;271:4573-4576.
26. An S, Knox KA. Ligation of CD40 rescues Ramos-Burkitt lymphoma B cells from calcium ionophore- and antigen receptor-triggered apoptosis by inhibiting activation of the cysteine protease CPP32/Yama and cleavage of its substrate PARP. FEBS Lett 1996;386:115-122.
27. Liu YJ, Mason DY, Johnson GD, et al. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur J Immunol 1991;21:1905-1910.
28. Donoghue S, Baden HS, Lauder I, et al. Immunohistochemical localization of caspase-3 correlates with clinical outcome in B-cell diffuse large-cell lymphoma. Cancer Res 1999;59:5386-5391.